A Phase 4 interventional study of EXPAREL in Hernia, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-08.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Hernia with a site in United States — 13 open to participants now, 14 under way, none of them phase 3. Hernia · United States.
Among the 92 studies in Hernia with a site in United States, this one is the 54th largest by enrollment of the 65 interventional ones that give a count, is one of 2 that started in 2012, is one of 10 in phase 4, and was the 41st registered.
257 studies on the registry are indexed under Hernia; 37 are open to participants now.
Browse Hernia studies →13 of the 92 studies in Hernia with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 50+ · Men only
Tissium · Sites in United States
Ages 22+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 60+
The Cleveland Clinic · Sites in United States
Ages 18+
Tela Bio Inc · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Hernia studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 80 across 167 interventional studies indexed under Hernia.
Median enrollment 83 across the 65 interventional studies, 110 across the 27 observational. Of the 68 that completed or were terminated, 31 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 92 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Pacira BioSciences, Inc. has 2 studies filed under Hernia — fewer than ten, so there is no comparison to draw.
5 of the studies in Hernia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04718168W.L.Gore & AssociatesGORE® ENFORM Biomaterial Product Study | 2026-12 |
| NCT07277946TissiumAtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE | 2026-12 |
| NCT07874724University of South FloridaCryoneurolysis for Abdominal Wall Relaxation Prior to Ventral Hernia Repair | 2027-03-01 |
| NCT05472987Lucas BeffaRobotic Versus Open Ventral Hernia Repair | 2027-08-01 |
| NCT07848386The University of Texas Health Science Center, HoustonPatient Priorities Aligned Discrete Decision Making for Older Adults With Multiple Chronic Conditions. | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 92 studies in Hernia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 4 study evaluating the effectiveness of EXPAREL when infiltrated into the the Transversus Abdominis Plane (TAP).
This is a prospective, open-label, non-randomized study evaluating the effectiveness of abdominal analgesia when using 266 mg EXPAREL to infiltrate into the TAP unilaterally.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
undiluted EXPAREL 266 mg
Drug: EXPAREL
single dose 266 mg of undiluted EXPAREL
Also known as: bupivacaine liposome injectable suspension
Overall Postsurgical Analgesic Use
The effectiveness of abdominal analgesia from the infiltration into the TAP as measured by the subject's overall postsurgical analgesic use in morphine equivalents (mg)
Time frame: 10 days
Postsurgical AEs and SAEs Through Day 30.
Adverse events and serious adverse events through Day 30 will be examined in order to assess the safety of EXPAREL.
Time frame: 30 days
Recruitment occurred between 20 July 2012 and 27 November 2012 at one site in the USA.
| Milestone | EXPAREL |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
The effectiveness of abdominal analgesia from the infiltration into the TAP as measured by the subject's overall postsurgical analgesic use in morphine equivalents (mg)
| mg (morphine equivalents) | EXPAREL |
|---|---|
| Overall Postsurgical Analgesic Use | 9.7 ± 17.41 |
Adverse events and serious adverse events through Day 30 will be examined in order to assess the safety of EXPAREL.
| AEs | EXPAREL |
|---|---|
| Postsurgical AEs and SAEs Through Day 30. | 0 |
Collected over Through Day 30. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL | — | 0/13 (0%) | 0/13 (0%) |
| Age, Categorical(Participants) | EXPAREL |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 13 |
| >=65 years | 0 |
| Age, Continuous(years) | EXPAREL |
|---|---|
| Mean | 45.7 ± 12.72 |
| Sex: Female, Male(Participants) | EXPAREL |
|---|---|
| Female | 3 |
| Male | 10 |
| Region of Enrollment(participants) | EXPAREL |
|---|---|
| United States | 13 |
The record gives a start of Apr 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine